Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 6Cisplatin 5Gemcitabine 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hyperthermic Intraperitoneal Chemotherapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3veliparib 2aflibercept 2X-Rays 2Temozolomide 2Taxes 2SS1(dsFv)PE38 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Irinotecan 2Interleukin-12 Subunit p35 2Immunoglobulin G 2Gene Expression Profiling 2Fluorouracil 2Drug Therapy 2Doxorubicin 2Disulfides 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Darbepoetin alfa × Gastrointestinal × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡